FDA fails to approve cholesterol drug for kidney disease
By Anna Yukhananov | WASHINGTON (Reuters) - US health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving ...
Merck Cholesterol Drug Helps Heart, FDA Label SaysThirdAge
FDA Turns Down Expanded Use of Merck's Vytorin and ZetiaBusinessWeek
New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes ...EON: Enhanced Online News (press release)

all 43 news articles »